Cleared Traditional

K885328 - RS-10 TELEPHONIC POLYSOMNOGRAPHY RECEIVER

K885328 is the FDA 510(k) clearance for RS-10 TELEPHONIC POLYSOMNOGRAPHY RECEIVER by Telediagnostic Systems, Inc.. It is a Class 2 Neurology device (product code GYE) cleared through the Traditional 510(k) pathway after a 84-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1989
Decision
84d
Days
Class 2
Risk

K885328 is an FDA 510(k) clearance for the RS-10 TELEPHONIC POLYSOMNOGRAPHY RECEIVER. Classified as Encephalogram Telemetry System (product code GYE), Class II - Special Controls.

Submitted by Telediagnostic Systems, Inc. (San Francisco, US). The FDA issued a Cleared decision on March 22, 1989 after a review of 84 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1855 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Telediagnostic Systems, Inc. devices

Submission Details

510(k) Number K885328 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 28, 1988
Decision Date March 22, 1989
Days to Decision 84 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
64d faster than avg
Panel avg: 148d · This submission: 84d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GYE Encephalogram Telemetry System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1855
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.